USP13: A Master Regulator of Protein Homeostasis in Health and Disease

Concept

Ubiquitin-Specific Protease 13 (USP13), a core member of the ubiquitin-specific protease (USP) subfamily of deubiquitinases (DUBs), is a pivotal molecular regulator of intracellular protein homeostasis—an essential process governing cellular function, survival and stress responses. Structurally, USP13 features the canonical USP family “finger-palm-thumb” catalytic domain with a conserved Cys-His-Asp triad, which mediates efficient deubiquitination by stabilizing oxyanion intermediates during isopeptide bond cleavage. Unique N- and C-terminal protein-interaction domains endow USP13 with the ability to form dynamic complexes with diverse substrates and regulatory factors, while its enzymatic activity, subcellular localization and substrate specificity are tightly modulated by post-translational modifications and cellular stimuli.

USP13 exerts context-dependent biological functions across physiological and pathological processes, acting as a key regulator of autophagy, mitochondrial quality control and endoplasmic reticulum stress responses. Notably, it displays a striking dual role in tumorigenesis—functioning as a tumor suppressor or oncogene depending on tumor type and molecular context—and is increasingly implicated in the pathogenesis of neurodegenerative diseases. As a critical node in multiple cellular regulatory networks, USP13 has emerged as a promising therapeutic target for cancer, neurodegeneration and metabolic disorders. ANT BIO PTE. LTD.’s UA sub-brand, a specialist in high-quality recombinant proteins, offers a human USP13 Protein—an indispensable research tool for dissecting USP13’s molecular mechanisms and advancing translational research into USP13-targeted therapies.

Research Frontier

Recent advances in molecular and cellular biology have unveiled the multifaceted and context-dependent functions of USP13, positioning it as a leading research hotspot in protein homeostasis, cancer biology and neurodegeneration research. Cutting-edge structural studies using X-ray crystallography have defined the precise catalytic mechanism of USP13, elucidating the role of its conserved Cys-His-Asp triad and autoinhibitory sequences in regulating enzymatic activity. Proteomic and phosphoproteomic analyses have identified critical phosphorylation sites (e.g., Ser452, Thr675) that modulate USP13’s substrate affinity and activity, as well as over 200 intracellular substrates—including key tumor suppressors, oncogenes and autophagy regulators—revealing the broad regulatory scope of USP13 in cellular processes.

In cancer research, a major breakthrough is the discovery of USP13’s dual oncogenic/tumor-suppressive role: it stabilizes the tumor suppressor p53 in breast and ovarian cancers, while promoting oncogenic signaling via c-Myc and HIF-1α stabilization in prostate cancer and gliomas. Recent studies have further uncovered USP13’s critical role in tumor metabolic reprogramming, where it drives the Warburg effect by stabilizing the glycolytic enzyme PKM2—an emerging target for combinatorial cancer therapy. In neurodegeneration research, novel findings link USP13 to tau proteinopathy in Alzheimer’s disease, α-synuclein aggregation in Parkinson’s disease and TDP-43 proteinopathy in amyotrophic lateral sclerosis (ALS), establishing USP13 as a potential therapeutic target for these incurable disorders.

The development of USP13-targeted therapeutics has also entered an exciting phase, with structure-based virtual screening identifying selective small-molecule inhibitors (e.g., DC-U13-022) with potent in vitro and in vivo activity against triple-negative breast cancer. Innovative strategies such as PROTAC-based degraders, prodrugs and photo-controllable regulators are now being explored to address the key challenge of USP13’s context-dependent functionality, representing the cutting edge of USP13 research and drug development.

Research Significance

Unraveling the molecular mechanisms and biological functions of USP13 holds profound scientific and clinical significance across multiple research disciplines, with far-reaching implications for basic cell biology, cancer research, neurodegeneration and regenerative medicine:

1. Advancing Protein Homeostasis Research: USP13 is a master regulator of the ubiquitin-proteasome system (UPS) and autophagy—two core pathways of protein homeostasis. In-depth study of USP13 enhances our understanding of how cells maintain protein balance under physiological and stress conditions, filling critical knowledge gaps in cellular quality control mechanisms.
2. Driving Precision Cancer Therapy: USP13’s dual role in tumorigenesis and its involvement in tumor metabolic reprogramming and immune evasion identify it as a novel and versatile therapeutic target for cancer. Developing USP13 modulators (agonists or inhibitors) offers new treatment options for a broad range of malignancies, including triple-negative breast cancer, prostate cancer and gliomas.
3. Exploring Neurodegeneration Therapies: USP13’s involvement in the key proteinopathies underlying Alzheimer’s, Parkinson’s and ALS positions it as a promising target for developing disease-modifying therapies for these devastating neurodegenerative disorders—an unmet clinical need with significant global health implications.
4. Elucidating Cellular Stress Responses: USP13 regulates mitochondrial quality control, autophagy and endoplasmic reticulum stress responses, acting as a “molecular tuner” of cellular stress signaling. Studying USP13 provides critical insights into how cells adapt to stress, with implications for treating metabolic disorders (e.g., diabetes) and liver disease linked to impaired stress responses.
5. Expanding Deubiquitinase Targeted Therapy: As a well-characterized USP family member, USP13 serves as a model for understanding the therapeutic potential of deubiquitinases—an emerging class of drug targets. Research on USP13 paves the way for developing targeted therapies for other DUBs involved in human disease.

High-purity recombinant USP13 protein is a foundational tool for all these research directions, and its availability directly determines the depth, reliability and translational potential of USP13-related research.

Related Mechanisms and Product Applications

Core Molecular Mechanisms and Biological Functions of USP13

1. Structural and Biochemical Properties

USP13 is a canonical USP family deubiquitinase with unique structural and biochemical features that govern its function:

• Catalytic Domain: The conserved “finger-palm-thumb” 3D conformation houses a Cys-His-Asp triad at the active site, which stabilizes oxyanion intermediates to facilitate specific cleavage of ubiquitin isopeptide bonds. USP13 cleaves K48- and K63-linked ubiquitin chains with high efficiency, with weaker activity toward K29 linkages.
• Autoinhibition and Post-Translational Regulation: Basal USP13 activity is low due to occlusion of the catalytic domain by autoinhibitory sequences; cellular stimuli (e.g., DNA damage, oxidative stress) induce conformational changes to expose the active site. Phosphorylation at Ser452 (CDK1-mediated) and Thr675 enhances substrate affinity by 8–10-fold and boosts enzymatic activity.
• Dynamic Subcellular Localization: USP13 is primarily cytoplasmic under normal conditions but translocates to mitochondria, the endoplasmic reticulum or nucleus during stress, enabling context-specific regulation of substrate proteins in distinct cellular compartments.
• Substrate Specificity: Proteomic studies have identified over 200 USP13 substrates, including p53, p62/SQSTM1, RPN13, c-Myc, HIF-1α and PKM2. USP13 exhibits “biphasic regulation” for some substrates—stabilizing them at low concentrations and promoting degradation at high concentrations—via modulation of polyubiquitination states.

2. Context-Dependent Biological Functions

USP13 exerts diverse and context-specific functions across physiological and pathological processes, acting as a key regulator of multiple cellular pathways:

• Dual Role in Tumorigenesis: In breast/ovarian cancers (wild-type p53), USP13 stabilizes p53 by deubiquitination, blocking MDM2-mediated degradation and acting as a tumor suppressor (high USP13 expression correlates with 35% higher 5-year survival). In prostate cancer/gliomas, USP13 stabilizes c-Myc/HIF-1α, enhances glycolysis and stem-like traits, and regulates PD-L1 stability—acting as an oncogene (USP13 knockout reduces xenograft growth by 60% and metastasis).
• Tumor Metabolic Reprogramming: USP13 binds and stabilizes the glycolytic enzyme PKM2, driving the Warburg effect (aerobic glycolysis). USP13 inhibition reduces glucose uptake by 45% and lactate secretion by 60%, restores mitochondrial oxidative phosphorylation and alleviates tumor microenvironment immunosuppression.
• Neurodegenerative Diseases: In Alzheimer’s disease, USP13 deubiquitinates tau, reducing neurofibrillary tangles (40% reduction in transgenic mice) and improving cognition (excessive activity causes toxic fragment accumulation). In Parkinson’s disease, USP13 aids α-synuclein clearance but loses activity when incorporated into aggregates. In ALS, USP13 modulates TDP-43 phase separation/nuclear transport, with USP13 SNPs linked to 2–3-fold higher sporadic ALS risk.
• Autophagy Regulation: USP13 deubiquitinates and stabilizes p62/SQSTM1, promoting autophagosome formation and substrate recruitment; interaction strength increases 3–5-fold during nutrient deprivation to boost autophagic flux. Pathological overactivation causes p62 accumulation and impaired autophagosome maturation (linked to fatty liver disease/pancreatic cancer).
• Mitochondrial Quality Control: USP13 interacts with mitophagy receptors FUNDC1/BNIP3 to mediate selective damaged mitochondria clearance, and translocates to the mitochondrial matrix under severe stress to cooperate with the PINK1/Parkin pathway. USP13 deficiency causes mitochondrial dysfunction (30% lower ATP, 2-fold higher ROS, calcium dyshomeostasis).
• ER Stress Response: USP13 modulates the ubiquitination status of UPR sensors (IRE1α, PERK), fine-tuning signal intensity—enhancing adaptive UPR during transient stress and accelerating UPR termination during chronic stress—via differential interactions with E3 ligases (HRD1, RNF185).

3. USP13-Targeted Therapeutic Strategies and Challenges

USP13 has emerged as a promising therapeutic target, with multiple strategies in development and key challenges to address:

• Small-Molecule Inhibitors: Structure-based virtual screening has identified selective inhibitors (e.g., dicoumarin derivatives, DC-U13-022) with IC50 = 3.2 μM, 20-fold improved potency and >100-fold selectivity over USP5/USP14; DC-U13-022 suppresses triple-negative breast cancer growth in animal models with no significant toxicity.
• Gene Therapy: CRISPRi-mediated USP13 repression reduces expression by 70–80% for ≥10 cell cycles in vitro; base editing corrects USP13 gain-of-function mutations in hereditary neuropathy models (delivery efficiency/off-target effects are key hurdles).
• Innovative Strategies: Prodrugs (tumor hypoxia/inflammation-activated), photo-controllable regulators (reversible light-mediated modulation) and PROTAC-based degraders (selective pathological USP13 variant degradation) are being developed to address context-dependent functionality.
• Key Challenges: The primary barrier to clinical translation is USP13’s opposing functions in different tissues/disease stages; precise spatiotemporal control of USP13 activity is required to avoid off-target effects and therapeutic toxicity.

USP13 Protein from ANT BIO PTE. LTD.: Core Applications and Research Value

ANT BIO PTE. LTD.’s UA sub-brand offers a high-quality Human USP13 Protein (Catalog No.: UA080069), expressed in E. coli with an unconjugated configuration. This recombinant protein is produced under rigorous quality control standards, ensuring high purity, structural integrity and biological activity, and serves as an indispensable research tool for investigating USP13’s molecular mechanisms, substrate interactions and enzymatic activity, as well as validating USP13-targeted therapeutic strategies.

Key Research Applications

1. Enzymatic Activity Assays: Used in in vitro deubiquitination assays to measure USP13’s catalytic activity toward different ubiquitin linkages (K48, K63, K29), and to assess the effects of post-translational modifications (phosphorylation) and small-molecule modulators on enzymatic function.
2. Protein-Protein Interaction Studies: Applied in pull-down, co-immunoprecipitation (Co-IP), surface plasmon resonance (SPR) and biolayer interferometry (BLI) assays to identify, verify and quantify USP13’s interactions with substrates (p53, p62, PKM2) and regulatory factors, and to screen for molecules that disrupt these critical interactions.
3. Structural Biology Research: Utilized for X-ray crystallography and cryo-electron microscopy to resolve the 3D structure of USP13 (alone and in complex with substrates/inhibitors), elucidating the molecular basis of its catalytic mechanism and substrate specificity—guiding rational design of USP13-targeted therapeutics.
4. High-Throughput Drug Screening: Serves as a key reagent in high-throughput screening platforms to identify and validate small-molecule inhibitors, agonists and PROTAC degraders targeting USP13, with applications in cancer and neurodegeneration drug development.
5. Cellular Function Assays: Transfected or added to cellular models to investigate USP13’s role in protein homeostasis, autophagy, mitochondrial quality control and tumor metabolic reprogramming, and to validate the functional consequences of USP13 modulation in health and disease.
6. Antibody Development and Validation: Used as an immunogen for the development of USP13-specific antibodies, and as a positive control to validate the specificity and affinity of anti-USP13 antibodies for use in Western blot, IHC and flow cytometry analyses of cellular and clinical samples.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.